돼지에서 만성 심장 마비 모델로 tachycardia 유발 심근

Executive Industry Relevance

Establishing a reliable chronic heart failure model is essential for evaluating hemodynamic responses and therapeutic efficacy in cardiovascular drug development. The tachycardia-induced cardiomyopathy model in swine offers a reproducible platform to study progressive ventricular dilation and systolic dysfunction, supporting target validation and mechanistic de-risking in heart failure pipelines. Its robustness enables consistent preclinical assessment of novel interventions, including mechanical circulatory supports and pharmacological agents.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses related to ventricular remodeling and hemodynamic stress in heart failure progression.
• Operational Value: Provides a stable, inducible platform for functional target validation through chronic pacing-induced cardiomyopathy.
• Predictive Value: Supports predictive confidence by modeling biventricular dilation and systolic dysfunction observed in human decompensated cardiomyopathy.

Screening & Assay Development

• Scientific Value: Generates quantifiable hemodynamic and structural endpoints (e.g., chamber dilation, ejection fraction) suitable for assay standardization.
• Operational Value: Facilitates reproducible monitoring via echocardiography and imaging, enabling consistent compound or device evaluation across studies.
• Scalability: The minimally invasive surgical approach allows for cohort expansion and longitudinal tracking in preclinical screening campaigns.

Translational & Preclinical Research

• Translational Value: Mirrors human dilated cardiomyopathy pathophysiology, enhancing relevance for preclinical-to-clinical translation.
• Mechanistic De-risking: Allows study of adaptation mechanisms and treatment responses in a controlled, progressive heart failure setting.
• Continuity: Supports seamless integration from discovery through preclinical validation of therapeutics targeting ventricular remodeling.

Pipeline & Workflow Integration

This model fits within the cardiovascular discovery continuum, particularly in early target validation and preclinical efficacy testing, where hemodynamic and structural readouts inform go/no-go decisions.

• Discovery Biology: Enables hypothesis testing around ventricular dilation, remodeling, and systolic dysfunction as key drivers of heart failure progression.
• Screening: Delivers reproducible quantitative outputs (e.g., ventricular volume, pressure gradients) essential for comparing intervention effects.
• Analytics: Provides echocardiographic and pressure-volume measurements that support statistical comparison across treatment groups.
• Translational Research: Models progressive heart failure with preserved structural and functional changes post-pacing, supporting longitudinal therapeutic assessment.
• Enterprise Reuse: Represents a reusable surgical and pacing platform applicable across multiple cardiovascular research programs.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by providing a controlled, reproducible model of ischemic-independent cardiomyopathy.
• Operational Value: Minimally invasive technique with standardized pacing parameters enhances lab-to-lab reproducibility.
• Strategic Value: Improves go/no-go decision confidence by reducing biological variability in heart failure phenotype expression.
• Portfolio Impact: Enables risk-adjusted prioritization of candidates based on consistent hemodynamic and functional outcomes.

Implementation Considerations

• Requires expertise in swine cardiology, surgical lead implantation, and pacemaker programming.
• Depends on fluoroscopy, echocardiography, and implantable pacemaker infrastructure for lead placement and monitoring.
• Necessitates cross-functional coordination between surgery, cardiology, and animal care teams for protocol adherence.
• Must account for swine growth and lead stability during extended pacing periods (4–8 weeks).
• Limited to models of tachycardia-induced cardiomyopathy; not applicable to ischemic or pressure-overload heart failure etiologies.

Biopharma FAQs